GATA4, GATA binding protein 4, 2626

N. diseases: 336; N. variants: 72
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.060 AlteredExpression phenotype BEFREE Furthermore, the expression of GATA4 was associated with tumor size, metastasis and poor prognosis. 30542490 2018
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.060 AlteredExpression phenotype BEFREE Results from a number of functional experiments, including cell proliferation analysis, cell cycle analysis, cell apoptosis assay and Transwell migration and invasion analyses, have suggested that high expression of GATA4 may facilitate proliferation and metastasis, and suppress apoptosis in ALL cells. 28849107 2017
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.060 Biomarker phenotype BEFREE GATA4 status was significantly associated with nuclear grade and van Nuys classification in DCIS and was positively associated with distant metastasis, histological grade and HER2 status, but negatively correlated with progesterone receptor labeling index in IDC. 24862985 2014
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.060 Biomarker phenotype BEFREE Here, we focus on GATA4 as a MYC target in the development of metastasis with origin in lung adenocarcinoma, the most common type of NSCLC. 23239811 2013
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.060 Biomarker phenotype BEFREE The methylation status of the CpG island promoter region of TRGs related to melanoma pathophysiology (WIF1, TFPI2, RASSF1A, RARbeta2, SOCS1, and GATA4) and a panel of MINT loci (MINT1, MINT2, MINT3, MINT12, MINT17, MINT25, and MINT31) in primary and metastatic tumors of different clinical stages (n=122) was assessed. 19223509 2009
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.060 Biomarker phenotype BEFREE We investigated GATA-4 and -5 by methylation-specific PCR (MSP) in normal and neoplastic pancreatic tissues, including isogenic xenografts or cultured cell lines derived from the coexistent primary cancer and/or metastases in patients with pancreatic carcinoma. 17912029 2007